Navigation Links
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
Date:3/9/2009

eceive 1200-mcg albinterferon alfa-2b; and 21.6% (162/750) in patients randomized to receive 180-mcg peginterferon alfa-2a.

About the Design of the ACHIEVE 1 Trial

In the randomized, multi-center, active-controlled non-inferiority ACHIEVE 1 Phase 3 trial, 1331 treatment-naive patients with genotype 1 chronic hepatitis C were initially assigned to one of three treatment groups, including two groups that received subcutaneously administered albinterferon alfa-2b once every two weeks at doses of 900 mcg or 1200 mcg, and an active control group that received peginterferon alfa-2a once weekly at a dose of 180 mcg - with all patients receiving daily oral ribavirin concomitantly. In January 2008, a dose modification was made for patients originally assigned to receive the 1200-mcg dose of albinterferon alfa-2b. These patients had their dose modified to 900-mcg albinterferon alfa-2b every two weeks. Following the dose modification, the study continued to follow all patients randomized into the trial on an intention-to-treat (ITT) basis according to their original dose assignment. The primary data analysis compares the 900-mcg albinterferon alfa-2b treatment group to the peginterferon alfa-2a treatment group. The trial included 48 weeks of treatment, and the primary efficacy endpoint was sustained virologic response (SVR), defined as undetectable viral load (HCV RNA<10 IU/mL) at Week 72 (24 weeks following completion of treatment). A total of 2,264 patients with chronic hepatitis C have participated in the two Phase 3 trials of albinterferon alfa-2b.

About Albinterferon Alfa-2b (Albuferon)

Albinterferon alfa-2b is a genetic fusion of human albumin and interferon alfa created using the proprietary HGS albumin-fusion technology. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for approximately 1
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Drug Development Program Started Based on CAP(R) Human Cell Line
2. Human Genome Sciences Announces Fourth-Quarter and Full-Year 2008 Financial Results and Key Developments
3. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
4. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
5. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
6. Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
9. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
10. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
11. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
(Date:8/29/2014)... BOSTON , Aug. 29, 2014   Vittamed Corporation ... Boston announced today that T. (Teo) Forcht ... to the company,s Board of Directors. " ... distinguished career in neurosurgery, medical innovation and venture capital," said ... are extremely delighted to add his clinical, strategic, and entrepreneurial ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" or ... today that it intends to release its financial results ... June 30, 2014 after market trading ends on Tuesday, ... a conference call for 4:30 p.m. U.S. EDT on ... 6:30 a.m. AEST), to review the Company,s financial results, commercial ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
(Date:8/29/2014)... Mirada, CA (PRWEB) August 29, 2014 ... healthcare organizations, acquired a new medical center from LAXMed. The ... airport and less than 2 miles west of the 405 ... center within Southern California. The new LAX center is located ... 90045. , The new Healthpointe LAX office ...
(Date:8/29/2014)... 2014 - Despite US Preventive Services Task Force recommendations ... several of which may be ameliorated through technological approaches ... Langone Medical Center published online August 21, 2014 in ... JGIM ). , David Levine, MD, MA, a third ... NYU Langone, and colleagues found that compared to usual ...
(Date:8/29/2014)... August 29, 2014 Today, Gen. Arthur ... Coalitions of America (CADCA) , the nation’s leading substance ... to President Obama’s intent to nominate Michael Botticelli as ... strongly supports President Obama’s decision to nominate Michael Botticelli ... ideal person to hold this important position at this ...
(Date:8/29/2014)... 29, 2014, 2 PM US Eastern Time)The current ... inject antibodies, commonly produced in animals, to neutralize ... from safety to difficulties in developing, producing and ... New research led by Charles Shoemaker, Ph.D., professor ... Health at the Cummings School of Veterinary Medicine ...
(Date:8/29/2014)... cancer patients lacking knowledge about the disease have difficulty ... quality of care and long-term results, new research suggests. ... age of 63. All were newly diagnosed with localized ... associated with greater difficulty deciding which treatment to choose ... the study found. "For prostate cancer, there is ...
Breaking Medicine News(10 mins):Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2Health News:Options for weight loss your primary care doctor might not know about 2Health News:CADCA Statement on Nomination of Michael Botticelli as U.S. Drug Czar 2Health News:Mice study shows efficacy of new gene therapy approach for toxin exposures 2Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
... , SATURDAY, Jan. 7 (HealthDay News) -- If you exercise ... stay safe, an expert advises. The main issue is hypothermia, ... Bryant, chief science officer at the American Council on Exercise. ... to control your body heat while exercising. A hat or helmet ...
... In a new review of imaging studies spanning more ... positron emission tomography (PET) safely and accurately detects dementia, ... elderly, Alzheimer,s disease. This research is featured in the ... . Researchers reviewed numerous PET studies to ...
... , FRIDAY, Jan. 6 (HealthDay News) -- Air ... high blood pressure in black American women, a new study ... the chances of acute cardiovascular events such as stroke and ... increases the likelihood of chronic diseases such as diabetes and ...
... HealthDay Reporter , FRIDAY, Jan. 6 (HealthDay News) -- ... have a different type of disease than those with more ... for them, new research suggests. "We are beginning to ... mechanisms," said Dr. John Fahy, director of the Airway Clinical ...
... the January issue of the Journal of the ... dose optimization in pediatric computed tomography (CT) scans. Approximately ... various pediatric clinical indications per year in the United ... most important aspect of reducing radiation dose with CT ...
... 6 (HealthDay News) -- Diabetes patients require continuous health ... study concludes. For the study, U.S. researchers analyzed ... care between 2005 and 2007 at 50 federally qualified ... reduced-cost care is provided to low-income patients whether they ...
Cached Medicine News:Health News:Safety Tips for Cold-Weather Exercise 2Health News:A decade of research proves PET effectively detects dementia 2Health News:A decade of research proves PET effectively detects dementia 3Health News:Smog Tied to Raised Risk of Chronic Illness in Black Women 2Health News:Study Offers Clues to Why Some Don't Benefit From Asthma Drugs 2Health News:Study Offers Clues to Why Some Don't Benefit From Asthma Drugs 3Health News:Experts offer pointers for optimizing radiation dose in pediatric CT 2Health News:Diabetes Care Thwarted by Unstable Health Insurance: Study 2
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
... developed to detect the presence of ... The information is clinically useful in ... - a3 chain antibody formation along ... primary diagnostic parameters. Since there are ...
GBM -Ab EIA Auto-Immune Markers 013-GBM-96 Glomerular Basement Membrane...
...
Medicine Products: